Ann: Appendix 4C - Quarterly - 31 December 2022, page-2

Extract from the Q:

"As part of ongoing business development activities, during the quarter Patrys initiated several
experiments at the request of a potential pharmaceutical partners. One of these is a sophisticated
experiment designed to examine the effects of both PAT-DX1 and PAT-DX3 in tumours with and
without mutations in their DNA damage repair (DDR) systems that have been implanted in the same
animal. This experiment is designed to confirm the synthetic lethality mode of action of deoxymabs
and will be completed and analysed during the current quarter (Q1 CY2023).
Also reflecting an active business development program Patrys has commenced work on a series of
experiments directed at conjugating a range of different gene-editing constructs to PAT-DX3. These
experiments are being conducted in collaboration with a potential licensee of the PAT-DX3 technology
and are expected to identify the preferred conjugation methods for attaching nucleic acid payloads to
PAT-DX3. These experiments will potentially create new intellectual property to strengthen Patrys’
business development offering in this commercially-active field."

Sounds good to me.
Not financial advice, DYOR